Among the 63 SCLC panel, 10–15% of the SCLC lines had an increased response to etoposide/carboplatin when simultaneously exposed to the PARP inhibitor talazoparib (Fig. 6D). The gene discussed is PARP1; the disease is small cell lung carcinoma.